- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03096275
Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu's Arteritis (CommittedTA)
August 28, 2023 updated by: Xinping Tian, Chinese SLE Treatment And Research Group
Comparison of the Efficacy of Mycophenolate Mofetil Combined With Methotrexate and Cyclophosphamide for the Treatment of Takayasu's Arteritis
Takayasu's arteritis(TAK) is a rare systemic vasculitis which can cause ischemia or inflammation of the involved organs and increase the overall mortality rate.The traditional treatment of TAK is primarily empirical.
The most commonly used drugs for treating active TAK are glucocorticosteroids(GC) and immunosuppressants.
However, the genital toxicity of CYC has limited its long term use.
In a pilot study carried out by the principal investigator of this study has shown that mycophenolate mofetil(MMF) combined with MTX is effective and with few adverse effects.
The purpose of this prospective open-label study is to compare the efficacy and safety of GC+MMF+MTX with GC+CYC followed by GC+AZA for the treatment of active TAK.
150 patients with active TAK will be recruited and randomized in a 2:1 ratio to GC+MMF+MTX group and C+CYC and AZA group.
Patients were followed for 52 weeks for efficacy and safety assessment.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Takayasu's arteritis(TAK) is a rare systemic vasculitis which mainly involves aorta and its major branches.
However,it is more prevalent in countries and areas along the silk road.Young women at child-bearing age is the most prevalent population.It can cause ischemia or inflammation of the involved organs and increase the overall mortality rate.Although it may be lethal in some patients,it is not well studied due to the rareness of the disease.The traditional treatment of TAK is primarily empirical.
The most commonly used drugs for treating active TAK are glucocorticosteroids(GC) and immunosuppressants including cyclophosphamide(CYC), methotrexate(MTX) and azathioprine(AZA) etc. However,no of these drugs have been well studied.
In addition, the genital toxicity of CYC, the first line medication for active TAK, has become the major limitation for its long term use for a chronic disease like TAK.
Therefore, new immunosuppressants with less toxicity,especially with much less genital toxicity and low malignancy risk is essentially necessary.
In a pilot study carried out by the principal investigator of this study has shown that mycophenolate mofetil(MMF) combined with MTX is effective and with few adverse effects.
The purpose of this prospective open-label study is to compare the efficacy and safety of GC+MMF+MTX with GC+CYC followed by GC+AZA for the treatment of active TAK.
150 patients with active TAK will be recruited and randomized in a 2:1 ratio to GC+MMF+MTX group and C+CYC and AZA group.
Patients were followed for 52 weeks to assess the efficacy and safety.
Study Type
Interventional
Enrollment (Actual)
138
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beijing, China, 100032
- Peking Union Medical College Hospital
-
Beijing, China, 100020
- Beijing ChaoYang Hospital
-
Beijing, China, 100053
- Beijing Xuanwu Hospital
-
Tianjin, China, 300052
- General Hospital of Tianjing Medical University
-
-
Hebei
-
Shijiazhuang, Hebei, China, 050051
- Hebei Provincial Hospital
-
-
Inner Mongolia
-
Huhehaote, Inner Mongolia, China, 010050
- The Affiliated Hospital of Inner Mongolia Medical University
-
-
Shanxi
-
Xian, Shanxi, China, 710032
- Xijing Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients older than 18 years-old either sex
- Patients with signed informed consent
- Fulfill the 1990 ACR Classification Criteria for TAK
- Patients with active disease according to GACTA criteria
Exclusion Criteria:
- Prior adverse events when treated with MTX that resulted in dose reduction or discontinuation;
- Prior treatment with MMF but failed response to MMF;
- Prior treatment with CYC but failed response to CYC;
- Renal dysfunction, defined as the estimated GFR <80% or serum creatinine level higher than 1.5 times of upper normal limit;
- Severe liver function damage defined by serum ALT or AST higher than 2 times of the upper normal limits;
- Uncontrolled diabetes melitus;
- Uncontrolled heart failure at baseline;
- Active infection including tuberculosis , hepatitis B virus, hepatitis C virus, HIV or bacterial or fungal infection;
- Active upper GI bleeding in the past 3 months.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MMF+MTX+Glucocorticoids
Patients were treated with Glucocorticoids combined with mycphenolate mofetil(MMF) as well as methotrexate(MTX) treatment for 52 weeks and were followed for 52 weeks.
|
Patients were treated with Glucocorticoids combined with methotrexate and mycophenolate mofetil
Other Names:
Patients in the experimental group and comparator group were treated with Glucocorticoids and then gradually tapered
Other Names:
Patients in the experimental group are treated with Glucocorticoids combined with MTX and MMF
Other Names:
|
Active Comparator: CYC/AZA+Glucocoticoids
Patients were treated with Glucocorticoids combined with cyclophosphamide(CYC)/azathioprine(AZA) for 52 weeks and were followed for 52 weeks
|
Patients in the experimental group and comparator group were treated with Glucocorticoids and then gradually tapered
Other Names:
Patients were treated with Glucocorticoids and cyclophosphamide sequentially with azathioprine
Other Names:
Patients in the active comparator group were treated with Glucocorticoids combined with CYC followed by AZA
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients with complete remission
Time Frame: 52 weeks
|
The proportion of patients who reached the pre-defined criteria of complete remission in both groups
|
52 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients with partial remission
Time Frame: 52 weeks
|
Proportion of patients who reached the pre-defined partial remission criteria of the disease
|
52 weeks
|
Safety profile of MMF combined with MTX
Time Frame: 52 weeks
|
Proportion of adverse events in both treatment groups
|
52 weeks
|
Rate of complications
Time Frame: 52 weeks
|
Proportion of patients with complications in both treatment group
|
52 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Xinping Tian, MD, Peking Union Medical College Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM, Fauci AS, Leavitt RY, Lie JT, Lightfoot RW Jr, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum. 1990 Aug;33(8):1129-34. doi: 10.1002/art.1780330811.
- Goel R, Danda D, Mathew J, Edwin N. Mycophenolate mofetil in Takayasu's arteritis. Clin Rheumatol. 2010 Mar;29(3):329-32. doi: 10.1007/s10067-009-1333-6.
- Shinjo SK, Pereira RM, Tizziani VA, Radu AS, Levy-Neto M. Mycophenolate mofetil reduces disease activity and steroid dosage in Takayasu arteritis. Clin Rheumatol. 2007 Nov;26(11):1871-5. doi: 10.1007/s10067-007-0596-z. Epub 2007 Feb 28.
- Daina E, Schieppati A, Remuzzi G. Mycophenolate mofetil for the treatment of Takayasu arteritis: report of three cases. Ann Intern Med. 1999 Mar 2;130(5):422-6. doi: 10.7326/0003-4819-130-5-199903020-00013.
- Ong LM, Hooi LS, Lim TO, Goh BL, Ahmad G, Ghazalli R, Teo SM, Wong HS, Tan SY, Shaariah W, Tan CC, Morad Z. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology (Carlton). 2005 Oct;10(5):504-10. doi: 10.1111/j.1440-1797.2005.00444.x.
- Li J, Yang Y, Zhao J, Li M, Tian X, Zeng X. The efficacy of Mycophenolate mofetil for the treatment of Chinese Takayasu's arteritis. Sci Rep. 2016 Dec 7;6:38687. doi: 10.1038/srep38687.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 16, 2017
Primary Completion (Actual)
November 11, 2022
Study Completion (Actual)
November 11, 2022
Study Registration Dates
First Submitted
March 13, 2017
First Submitted That Met QC Criteria
March 29, 2017
First Posted (Actual)
March 30, 2017
Study Record Updates
Last Update Posted (Actual)
August 30, 2023
Last Update Submitted That Met QC Criteria
August 28, 2023
Last Verified
April 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PUMCHCSTAR-006
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Takayasu Arteritis
-
Assistance Publique - Hôpitaux de ParisChugai PharmaceuticalCompleted
-
Instituto Nacional de Cardiologia Ignacio ChavezCompleted
-
AbbVieActive, not recruitingTakayasu Arteritis (TAK)Argentina, Brazil, China, Japan, Korea, Republic of, Turkey
-
Assistance Publique - Hôpitaux de ParisRecruitingArteritis | Systemic Vasculitis | Arteritis, TakayasuFrance
-
Chinese Pulmonary Vascular Disease Research GroupRecruitingTakayasu Arteritis With Pulmonary Artery Involvement | Percutaneous Transluminal Pulmonary Angioplasty | PAH Targeted MedicationChina
-
Beijing Institute of Heart, Lung and Blood Vessel...Peking University People's Hospital; Shanghai Zhongshan HospitalRecruiting
-
University of Sao PauloFederal University of São PauloUnknown
-
University of PennsylvaniaNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaboratorsCompletedTakayasu's ArteritisUnited States, Canada
-
Assistance Publique - Hôpitaux de ParisNot yet recruiting
Clinical Trials on MMF
-
Peking University People's HospitalUnknownNatural Killer Cell Mediated ImmunityChina
-
AO Clinical Investigation and Publishing DocumentationRecruitingMandibular FracturesGermany, United States
-
Hannover Medical SchoolCompleted
-
AZ-VUBUnknownDiabetes Mellitus, Type 1Belgium
-
Nanfang Hospital of Southern Medical UniversityRecruiting
-
University of Sao Paulo General HospitalCompleted
-
Fuzhou General HospitalUnknownKidney Transplant | Chronic Allograft NephropathyChina
-
University Hospital, LimogesNot yet recruitingLiver Transplantation | ImmunosuppressionFrance
-
The University of Hong KongUnknown
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingMycophenolate Mofetil | Henoch-Schönlein Purpura | Gastrointestinal InjuryChina